RVNC Annual CFF
$136.57 M
-$195.13 M-58.83%
31 December 2023
Summary:
As of January 20, 2025, RVNC annual cash flow from financing activities is $136.57 million, with the most recent change of -$195.13 million (-58.83%) on December 31, 2023. During the last 3 years, it has fallen by -$194.92 million (-58.80%). RVNC annual CFF is now -58.83% below its all-time high of $331.69 million, reached on December 31, 2022.RVNC Cash From Financing Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
RVNC Quarterly CFF
-$6.09 M
-$2.67 M-78.30%
30 September 2024
Summary:
As of January 20, 2025, RVNC quarterly cash flow from financing activities is -$6.09 million, with the most recent change of -$2.67 million (-78.30%) on September 30, 2024. Over the past year, it has dropped by -$43.55 million (-116.25%). RVNC quarterly CFF is now -102.30% below its all-time high of $264.35 million, reached on March 31, 2020.RVNC Quarterly CFF Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
RVNC TTM CFF
$81.70 M
-$43.55 M-34.77%
30 September 2024
Summary:
As of January 20, 2025, RVNC TTM cash flow from financing activities is $81.70 million, with the most recent change of -$43.55 million (-34.77%) on September 30, 2024. Over the past year, it has dropped by -$50.33 million (-38.12%). RVNC TTM CFF is now -78.48% below its all-time high of $379.59 million, reached on June 30, 2020.RVNC TTM CFF Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
RVNC Cash From Financing Performance
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly | TTMTTM |
|---|---|---|---|
| 1 y1 year | -58.8% | -116.3% | -38.1% |
| 3 y3 years | -58.8% | -144.3% | -15.6% |
| 5 y5 years | +7563.7% | -7414.8% | -63.1% |
RVNC Cash From Financing High & Low
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | TTM vs highTTM vs high | TTM vs lowTTM vs low | |
|---|---|---|---|---|---|---|---|
| 3 y | 3-year | -58.8% | +357.2% | -102.9% | +1.4% | -75.8% | +173.5% |
| 5 y | 5-year | -58.8% | +357.2% | -102.3% | +1.4% | -78.5% | +173.5% |
| alltime | all time | -58.8% | +5269.1% | -102.3% | +1.4% | -78.5% | +3192.3% |
Revance Therapeutics Cash From Financing History
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Sept 2024 | - | -$6.09 M(+78.3%) | $81.70 M(-34.8%) |
| June 2024 | - | -$3.41 M(-103.7%) | $125.25 M(-44.6%) |
| Mar 2024 | - | $92.83 M(-5798.5%) | $226.13 M(+65.6%) |
| Dec 2023 | $136.57 M(-58.8%) | -$1.63 M(-104.3%) | $136.57 M(+3.4%) |
| Sept 2023 | - | $37.46 M(-61.6%) | $132.02 M(-56.8%) |
| June 2023 | - | $97.47 M(+2885.3%) | $305.95 M(+33.2%) |
| Mar 2023 | - | $3.27 M(-152.9%) | $229.65 M(-30.8%) |
| Dec 2022 | $331.69 M(+1010.5%) | -$6.17 M(-102.9%) | $331.69 M(-1.9%) |
| Sept 2022 | - | $211.39 M(+898.8%) | $338.27 M(+171.9%) |
| June 2022 | - | $21.16 M(-79.9%) | $124.39 M(+17.2%) |
| Mar 2022 | - | $105.31 M(>+9900.0%) | $106.14 M(+255.3%) |
| Dec 2021 | $29.87 M(-91.0%) | $405.00 K(-116.3%) | $29.87 M(-69.1%) |
| Sept 2021 | - | -$2.49 M(-185.6%) | $96.79 M(-1.8%) |
| June 2021 | - | $2.91 M(-90.0%) | $98.59 M(+2.5%) |
| Mar 2021 | - | $29.04 M(-56.9%) | $96.18 M(-71.0%) |
| Dec 2020 | $331.48 M(+49.5%) | $67.32 M(-9899.7%) | $331.48 M(-12.5%) |
| Sept 2020 | - | -$687.00 K(-237.4%) | $378.99 M(-0.2%) |
| June 2020 | - | $500.00 K(-99.8%) | $379.59 M(+0.1%) |
| Mar 2020 | - | $264.35 M(+130.2%) | $379.14 M(+71.0%) |
| Dec 2019 | $221.66 M(>+9900.0%) | $114.83 M(<-9900.0%) | $221.66 M(+107.2%) |
| Sept 2019 | - | -$81.00 K(-288.4%) | $106.99 M(-0.9%) |
| June 2019 | - | $43.00 K(-100.0%) | $107.97 M(-2.6%) |
| Mar 2019 | - | $106.87 M(>+9900.0%) | $110.87 M(+6121.8%) |
| Dec 2018 | $1.78 M | $164.00 K(-81.7%) | $1.78 M(-98.9%) |
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Sept 2018 | - | $895.00 K(-69.6%) | $160.28 M(-4.9%) |
| June 2018 | - | $2.94 M(-232.5%) | $168.51 M(-0.1%) |
| Mar 2018 | - | -$2.22 M(-101.4%) | $168.72 M(-13.9%) |
| Dec 2017 | $195.94 M(-7516.5%) | $158.67 M(+1639.2%) | $195.94 M(+435.2%) |
| Sept 2017 | - | $9.12 M(+189.3%) | $36.61 M(+36.5%) |
| June 2017 | - | $3.15 M(-87.4%) | $26.82 M(+16.8%) |
| Mar 2017 | - | $25.00 M(-3842.7%) | $22.96 M(-969.1%) |
| Dec 2016 | -$2.64 M(-101.9%) | -$668.00 K(+0.6%) | -$2.64 M(-102.1%) |
| Sept 2016 | - | -$664.00 K(-6.1%) | $125.08 M(-7.4%) |
| June 2016 | - | -$707.00 K(+17.2%) | $135.09 M(-6.5%) |
| Mar 2016 | - | -$603.00 K(-100.5%) | $144.55 M(+1.4%) |
| Dec 2015 | $142.59 M(-37.8%) | $127.05 M(+1258.7%) | $142.59 M(+1364.0%) |
| Sept 2015 | - | $9.35 M(+6.8%) | $9.74 M(-1460.3%) |
| June 2015 | - | $8.75 M(-441.5%) | -$716.00 K(-100.6%) |
| Mar 2015 | - | -$2.56 M(-55.8%) | $120.57 M(-47.4%) |
| Dec 2014 | $229.09 M(+324.3%) | -$5.80 M(+425.0%) | $229.09 M(-10.0%) |
| Sept 2014 | - | -$1.10 M(-100.8%) | $254.68 M(+0.4%) |
| June 2014 | - | $130.04 M(+22.7%) | $253.60 M(+94.6%) |
| Mar 2014 | - | $105.95 M(+435.4%) | $130.29 M(+141.3%) |
| Dec 2013 | $53.99 M(+296.4%) | $19.79 M(-1003.6%) | $53.99 M(+57.9%) |
| Sept 2013 | - | -$2.19 M(-132.5%) | $34.20 M(-6.0%) |
| June 2013 | - | $6.73 M(-77.3%) | $36.39 M(+22.7%) |
| Mar 2013 | - | $29.66 M | $29.66 M |
| Dec 2012 | $13.62 M(-74.8%) | - | - |
| Dec 2011 | $54.07 M | - | - |
FAQ
- What is Revance Therapeutics annual cash flow from financing activities?
- What is the all time high annual CFF for Revance Therapeutics?
- What is Revance Therapeutics annual CFF year-on-year change?
- What is Revance Therapeutics quarterly cash flow from financing activities?
- What is the all time high quarterly CFF for Revance Therapeutics?
- What is Revance Therapeutics quarterly CFF year-on-year change?
- What is Revance Therapeutics TTM cash flow from financing activities?
- What is the all time high TTM CFF for Revance Therapeutics?
- What is Revance Therapeutics TTM CFF year-on-year change?
What is Revance Therapeutics annual cash flow from financing activities?
The current annual CFF of RVNC is $136.57 M
What is the all time high annual CFF for Revance Therapeutics?
Revance Therapeutics all-time high annual cash flow from financing activities is $331.69 M
What is Revance Therapeutics annual CFF year-on-year change?
Over the past year, RVNC annual cash flow from financing activities has changed by -$195.13 M (-58.83%)
What is Revance Therapeutics quarterly cash flow from financing activities?
The current quarterly CFF of RVNC is -$6.09 M
What is the all time high quarterly CFF for Revance Therapeutics?
Revance Therapeutics all-time high quarterly cash flow from financing activities is $264.35 M
What is Revance Therapeutics quarterly CFF year-on-year change?
Over the past year, RVNC quarterly cash flow from financing activities has changed by -$43.55 M (-116.25%)
What is Revance Therapeutics TTM cash flow from financing activities?
The current TTM CFF of RVNC is $81.70 M
What is the all time high TTM CFF for Revance Therapeutics?
Revance Therapeutics all-time high TTM cash flow from financing activities is $379.59 M
What is Revance Therapeutics TTM CFF year-on-year change?
Over the past year, RVNC TTM cash flow from financing activities has changed by -$50.33 M (-38.12%)